Get the Stockscreener App
11.12
2.77%
0.30
After Hours:
11.17
0.05
+0.45%
Organon Co stock is traded at $11.12, with a volume of 2.93M.
It is up +2.77% in the last 24 hours and down -28.81% over the past month.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
See More
Previous Close:
$10.82
Open:
$10.96
24h Volume:
2.93M
Relative Volume:
0.87
Market Cap:
$2.91B
Revenue:
$6.41B
Net Income/Loss:
$1.30B
P/E Ratio:
2.2063
EPS:
5.04
Net Cash Flow:
$646.00M
1W Performance:
-2.71%
1M Performance:
-28.81%
6M Performance:
-36.96%
1Y Performance:
-37.77%
1-Day Range:
$10.88
$11.22
1-Week Range:
$10.75
$11.66
52-Week Range:
$10.75
$23.10
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
11.12 | 2.91B | 6.41B | 1.30B | 646.00M | 5.04 |
|
LLY
Lilly Eli Co
|
839.96 | 677.40B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
157.47 | 371.98B | 89.33B | 21.81B | 18.06B | 8.99 |
|
ABBV
Abbvie Inc
|
172.99 | 316.82B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
58.08 | 293.24B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.86 | 216.19B | 51.72B | 11.94B | 13.81B | 5.88 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
(OGN) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Ganirelix Market Is Booming Worldwide 2025-2032 | Organon & Co.,Merck & Co., Inc.,Ferring Pharmaceuticals - openPR.com
Organon stock hits 52-week low at $10.92 amid market challenges By Investing.com - Investing.com South Africa
Organon stock hits 52-week low at $10.92 amid market challenges - Investing.com Australia
Organon expands board with new director from Takeda - Investing.com
Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors - Bluefield Daily Telegraph
Takeda President Ramona Sequeira Joins Organon Board: Major Win for Women's Health Giant - Stock Titan
Organon & CoExpects $6 Million Milestone Expense In Q1 2025 - marketscreener.com
Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025 - Bluefield Daily Telegraph
Organon Earnings Alert: Q1 2025 Results Coming May 1 with $6M Milestone Expenses - Stock Titan
Organon (OGN) Laps the Stock Market: Here's Why - Yahoo Finance
EU regulator reviews anti-baldness drugs over concerns of suicidal thoughts - marketscreener.com
Organon's NDURVA Cream Gets Health Canada Approval for Plaque Psoriasis Treatment - marketscreener.com
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Yahoo Finance
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11 - 뉴스와이어
Organon's Ba2 CFR affirmed by Moody's, outlook revised to negative - Investing.com Australia
Organon’s Ba2 CFR affirmed by Moody’s, outlook revised to negative - Investing.com Canada
Strength Seen in Organon (OGN): Can Its 8.5% Jump Turn into More Strength? - Nasdaq
Organon (OGN) Sees Flat Revenue, Downgraded Full-Year Outlook - GuruFocus
Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment - Yahoo Finance
Organon Enters Oversold Territory - Nasdaq
Organon (OGN): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Organon (OGN): Company Profile, Stock Price, News, Rankings - Fortune
Organon stock hits 52-week low at $13.84 amid market challenges - Investing.com Canada
Organon stock hits 52-week low at $13.84 amid market challenges By Investing.com - Investing.com South Africa
Organon (OGN) Stock Moves -1.83%: What You Should Know - Yahoo Finance
Why Organon (OGN) Could Beat Earnings Estimates Again - Yahoo Finance
Organon acquires Actemra biosimilar’s US rights from Biogen - Pharmaceutical Technology
Organon Looks To Tap Tocilizumab Potential Following Biogen Acquisition - insights.citeline.com
Organon acquires US rights to arthritis biosimilar TOFIDENCE By Investing.com - Investing.com South Africa
Organon Expands Biosimilar Portfolio With Tofidence Acquisition - Managed Healthcare Executive
Organon Acquires TOFIDENCE - citybiz
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock - Yahoo Finance
Organon Acquires Tofidence for Intravenous Infusion in US - MarketScreener
Organon buys rights to Biogen’s biosimilar targeting Roche’s Actemra - Seeking Alpha
Organon acquires rights for Tofidence from Biogen - TipRanks
Organon acquires US rights to arthritis biosimilar TOFIDENCE - Investing.com
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S. - Bluefield Daily Telegraph
Organon Claims US Market Leadership with Groundbreaking Tocilizumab Biosimilar Deal - Stock Titan
Natixis Advisors LLC Decreases Stock Holdings in Organon & Co. (NYSE:OGN) - MarketBeat
Organon (OGN) Stock Moves -0.34%: What You Should Know - Yahoo Finance
Organon, Henlius Say EMA Validates Marketing Authorization Application for Proposed Breast Cancer Drug - MarketScreener
European Medicines Agency (EMA) Validates Henlius And Organon Filing For Perjeta® (Pertuzumab) Biosimilar Candidate HLX11 - MarketScreener
Organon, Shanghai Henlius Biotech: EMA validates MAA for HLX11 - TipRanks
Major Win: Organon's Breast Cancer Drug Gets Critical EMA Validation After Trial Success - Stock Titan
Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Organon & Co. (OGN): A Deep Value Play with a 35.96% Upside Potential and an Attractive 7.61% Dividend Yield - DirectorsTalk Interviews
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Organon Co Stock (OGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Karp Daniel | Executive VP, Corp. Dev. |
Mar 31 '25 |
Option Exercise |
0.00 |
34,677 |
0 |
44,515 |
| Stahler Rachel A | Chief Information Officer |
Mar 31 '25 |
Option Exercise |
0.00 |
18,334 |
0 |
78,994 |
| WALSH MATTHEW M | Chief Financial Officer |
Mar 31 '25 |
Option Exercise |
0.00 |
34,870 |
0 |
136,903 |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO |
Mar 31 '25 |
Option Exercise |
0.00 |
8,865 |
0 |
20,552 |
| Weaver Kirke | Gen. Counsel & Corp. Secy. |
Mar 31 '25 |
Option Exercise |
0.00 |
21,376 |
0 |
45,668 |
| DiMarco Kathryn | Corporate Controller |
Mar 31 '25 |
Option Exercise |
0.00 |
23,435 |
0 |
40,211 |
| Nisita Vittorio | Head of Global Business Svcs |
Mar 31 '25 |
Option Exercise |
0.00 |
13,231 |
0 |
44,803 |
| Morrissey Joseph T. Jr. | Head of Manufacturing |
Mar 31 '25 |
Option Exercise |
0.00 |
21,483 |
0 |
73,275 |
| Ali Kevin | Chief Executive Officer |
Mar 31 '25 |
Option Exercise |
0.00 |
109,204 |
0 |
260,687 |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO |
Nov 07 '24 |
Option Exercise |
0.00 |
6,446 |
0 |
13,987 |
0.45%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):